Iwasaki, Takeshi
Nakabo, Shuichiro
Terao, Chikashi
Murakami, Kosaku
Nakashima, Ran
Hashimoto, Motomu
Imura, Yoshitaka
Yukawa, Naoichiro
Yoshifuji, Hajime
Miura, Yasuo
Yurugi, Kimiko
Maekawa, Taira
van Delft, Myrthe A. M.
Trouw, Leendert A.
Fujii, Takao
Mimori, Tsuneyo
Ohmura, Koichiro http://orcid.org/0000-0003-2927-9159
Funding for this research was provided by:
JSPS KAKENHI (26460649)
Article History
Received: 23 June 2020
Accepted: 8 October 2020
First Online: 19 October 2020
Ethics approval and consent to participate
: The present study was performed in accordance with the Helsinki Declaration and was approved by Kyoto University Graduate School and Faculty of Medicine Ethics Committee (approval numbers: E458 and R1540).
: Not applicable.
: M Hashimoto: Received a research and/or speaker fee from Bristol-Myers, Eisai, Eli Lilly, and Tanabe-Mitsubishi. He belongs to the department that is financially supported by five pharmaceutical companies (Mitsubishi-Tanabe Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., Asahi-Kasei Pharma Corp., and UCB Japan Co., Ltd.).T Fujii: Received speaking fees and/or honoraria from Abbvie, Astellas, Asahi-kasei, Chugai, Eli Lilly, Eisai, Janssen, Kissei, Mitsubishi-Tanabe, Ono, Pfizer, Sanofi, Taisho Toyama, Takeda, and UCB, and has received research grants from AbbVie, Ayumi, Asahi-kasei, Astellas, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Kissei, Mitsubishi-Tanabe, Pfizer, Nippon-Kayaku, Ono, Takeda, and UCB.K Ohmura: Received research grants and/or speaker’s fees from Abbvie, Actelion, Asahikasei Pharma, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, JB, Mitsubishi Tanabe, Nippon Kayaku, Nippon Shinyaku, Novartis, Sanofi, and Takeda.